Molina (MOH) Q4 2025 Earnings Call Transcript

Molina Healthcare reported 2025 adjusted EPS of $11.03, far below its initial $24.50 guide, and posted a Q4 adjusted loss of $2.75 per share on $10.7 billion of premium revenue. Management guided 2026 adjusted EPS to at least $5 and premium revenue to about $42 billion, pressured by a 92.9% Medicaid MCR, a planned MAPD exit, and a $2.3 billion decline in Marketplace premium. Offsetting factors include a new $6 billion annualized Florida CMS contract, embedded earnings above $11 per share, and strong capital metrics with 305% RBC and $223 million of parent cash.

Analysis

MOH is telegraphing that 2026 is a deliberate reset year, not a growth year, and that matters more for the stock than the headline EPS cut. The market is likely underestimating how much of the “earnings power” story is now a timing story: a large chunk of embedded value depends on rate restoration, Florida ramp normalization, and a cleaner Medicare mix, all of which are back-half or multi-year variables. That makes the 2H26 setup fragile even if the balance sheet looks adequate on paper.

The more important second-order effect is competitive. MOH’s aggressive retreat from Marketplace should relieve some near-term volatility but also signals that the lowest-quality risk is now being consciously shed across the managed-care group; that can tighten pricing discipline elsewhere, especially if peers are forced to chase volume into underpriced ACA books. At the same time, Florida creates a new “prove-it” burden: if the contract ramps hot, reported margins stay pressured while the long-dated earnings thesis remains intact; if it ramps poorly, investors will question the credibility of the embedded-earnings bridge.

The contrarian read is that the stock may already be pricing in the obvious downside—near-term EPS compression and weak 2026 optics—while missing the optionality from Medicaid rate resets. But the offset is duration: the thesis only works if states actually rebase rates faster than trend, and that is usually a slower political process than management implies. In other words, the bull case is real but the catalyst path is long, lumpy, and vulnerable to one or two adverse state actions that can re-open the MCR gap by several points.

Key Decisions for Investors

• Short MOH outright into the next 4-8 weeks on any relief rally: the guide is a credibility reset and the stock still faces multiple estimate cuts as consensus adjusts to the 2026 MCR and Medicare drag.
• Best relative-value expression: long UNH / short MOH for 3-6 months. If managed care multiples re-rate on quality, MOH should lag because its earnings recovery depends on rate timing, not controllable execution.
• Sell 2026 MOH call spreads or buy put spreads around the Florida implementation window. Risk/reward favors downside in reported results if the new contract runs hotter than modeled before target margins appear.
• For a catalyst trade, consider a small tactical long into evidence of Medicaid rate resets only if state filings start moving in MOH’s favor; until then, the stock is a show-me story with asymmetric negative revision risk.
• Avoid pairing MOH with other Medicaid-heavy names as a sector hedge; the company-specific issue is guide credibility and ACA runoff, not broad healthcare beta.